Articles by Amy Smith - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe
  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Amy Smith

Determining Potency of Preclinical Dose Formulations

Multiple factors arising during sample preparation can affect potency measurements.
Oct 2, 2012
By: Ashley Sanchez, Melissa Whitsel, Amy Smith

Potency is a required measurement to determine the amount of active ingredient contained in a preclinical dose formulation. Assessing potency ensures that the test system receives the appropriate amount of active ingredient based on predetermined specifications.

How to Assess Preclinical Dose Formulation Homogeneity

Uniform dose formulation is key to meeting safety study requirements.
Jul 2, 2012
By: Amy Smith, Melissa Whitsel

Uniform dose formulation is key to meeting safety study requirements.

Preclinical Dose-Formulation Stability

When designing stability protocols, formulation, storage, and dosing conditions must be assessed.
Jun 2, 2012
By: Amy Smith, Melissa Whitsel

When designing stability protocols, formulation, storage, and dosing conditions must be assessed.

Preclinical Dose-Formulation Stability

A number of factors need to be considered when evaluating preclinical dose-formulation stability. The authors discuss formulation, storage and dosing conditions.
Jun 1, 2012
By: Amy Smith, Melissa Whitsel

A number of factors need to be considered when evaluating preclinical dose-formulation stability. The authors discuss formulation, storage and dosing conditions.

ADVERTISEMENT
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FindPharma Custom Search
Featured Jobs

More Jobs
Click here